YOU’VE GOT aHUS!
The third article in the series about the aHUS Diagnosis Process is published today. Rare Disease Day 2022 The article covers…
One genetic problem but two diseases
Take "diacylglycerol kinase " and add a "syndrome" throw in a letter from the Greek alphabet " ε" and you have…
TMA: the Need for a Multidisciplinary Team Approach
Can MedEd Encourage Specialists to Form TMA Teams? Tiny clots which form in the body’s small blood vessels - in brief,…
Ravulizumab is not quite eculizumab
Ravulizumab is becoming a treatment of choice for aHUS in countries where access is funded. Though eculizumab will still have a…
aHUS Diagnosis Process-First Report
The first report on what 227 aHUS patients from around the world told us about their aHUS diagnosis experience and their…
Help needed to join the aHUS dots
Article No 395 25 November 2020 This was a call to action to the Global aHUS community.( Results to come) It…
Ravulizumab costs less over a life time
Article No 394 23 November 2020 In an article on 16 October 2020 (No 388) aHUS Global Action derived a cost…
The aHUS Diagnosis Process
Article No 389 27 October 2020 A process is a series of steps. Diagnosis is a process. A medical diagnosis is…
Atypical HUS & World Thrombosis Day
World Thrombosis Day is held annually on 13 October to help raise awareness of causes, dangers, and risk factors for blood clot formation. Thrombosis is the formation of potentially deadly blood clots in an artery or vein. People with the rare disease atypical HUS can experience organ damage from small vessel blood clots & need to be alert to signs of thrombosis.